



HAL
open science

Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year

Élodie Pierre, Adélaïde Pladys, Sahar Bayat, Pierre Tattevin, Cécile Vigneau

► **To cite this version:**

Élodie Pierre, Adélaïde Pladys, Sahar Bayat, Pierre Tattevin, Cécile Vigneau. Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year. *Vaccine*, 2023, 41 (24), pp.3655-3662. 10.1016/j.vaccine.2023.05.003 . hal-04114346

HAL Id: hal-04114346

<https://ehesp.hal.science/hal-04114346>

Submitted on 21 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year

Élodie Pierre^a, Adélaïde Pladys^b, Sahar Bayat-Makoei^b, Pierre Tattevin^{c,*1}, and Cécile Vigneau^{a,d,1}

^a Pontchaillou Univ Hosp, Nephrology, Rennes, France

^b Univ Rennes, EHESP, CNRS, Inserm, Arènes - UMR 6051, RSMS - U1309 - Rennes, France

^c Pontchaillou Univ Hosp, Infectious Diseases and Intensive Care Unit, Rennes, France

^d Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France

* Corresponding author at: Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes 35033, France

E-mail address: pierre.tattevin@chu-rennes.fr (P. Tattevin).

¹ Pierre Tattevin and Cécile Vigneau co-directed this work

Keywords: end-stage renal disease; dialysis; pneumococcal vaccination; vaccination coverage; mortality

1 **Abstract**

2 *Objectives.* Pneumococcal immunization is recommended in dialysis patients. We aimed to
3 estimate pneumococcal vaccination coverage among patients who initiate dialysis in France,
4 and its association with mortality.

5 *Methods.* Data were extracted from two prospective national databases, merged using a
6 deterministic linkage method: renal epidemiology and information network (REIN) registry,
7 which includes all patients on dialysis and kidney transplants recipients in France, and the
8 national health insurance information system (SNIIRAM) which collects individual data on
9 health expenditure reimbursement, including vaccines. We enrolled all patients who initiated
10 chronic dialysis in 2015. Data on health status at dialysis initiation, dialysis modalities, and
11 pneumococcal vaccine prescribed from 2 years before to 1 year after dialysis start were
12 collected. Univariate and multivariate Cox proportional hazard models were used to assess one-
13 year all-cause mortality.

14 *Results.* Among the 8,294 incident patients included, 1,849 (22.3%) received at least one
15 pneumococcal vaccine before (n=542, 6.5%), or after (n=1,307, 15.8%) dialysis start, as
16 follows: 13-valent pneumococcal conjugated vaccine (PCV13) followed by 23-valent
17 pneumococcal polysaccharide vaccine (PPSV23), n=938 (50.7%); only PPSV23, n=650
18 (35.1%); or only PCV13, n=261 (14.1%). Vaccinated patients were younger (mean, 66.5 ± 14.8
19 years vs. 69.0 ± 14.9 years, $P \leq 0.001$), more likely to suffer from glomerulonephritis (17.0%
20 vs. 11.0%, $P \leq 0.001$), and less likely to start dialysis in emergency (27.2% vs. 31.1%,
21 $P=0.001$). On multivariate analysis, patients who received PCV13 and PPSV23, or only PCV13
22 were less likely to die (respectively, HR=0.37; 95%CI 0.28-0.51, and HR=0.35; 95%CI 0.19-
23 0.65).

24 *Conclusions.* Pneumococcal immunization with PCV13 followed by PPSV23, or with PCV13
25 alone, but not with PPSV23 alone, is independently associated with decreased one year-
26 mortality in patients who start dialysis.

27

28 1. Introduction

29 Mortality among patients with chronic kidney diseases (CKD) who require dialysis
30 remains high despite recent improvement. Infection is the second leading cause of death in
31 patient with end-stage renal diseases (ESRD), after cardiovascular events (1). Prevention is key
32 to reduce infection-related morbidity and mortality. *Streptococcus pneumoniae* is a major cause
33 of community-acquired pneumonia (CAP), in adults and children, and invasive pneumococcal
34 diseases (IPD) disproportionately affect patients with ESRD (2–4). Of note, ESRD is also
35 associated with worse outcomes in patients who develop CAP or IPD (5–7). Anti-pneumococcal
36 vaccines are recommended in patients with CKD (8)(9)(10), although clinical data on the
37 impact of pneumococcal immunization in haemodialysis patients remain scarce. Patients with
38 ESRD have impaired immune response to different vaccines (11), including anti-pneumococcal
39 vaccines (12,13). During the study period, and up to March 2023, two different types of
40 pneumococcal vaccines have been available in France: a 23-valent pneumococcal
41 polysaccharide vaccine (PPSV23), and a 13-valent pneumococcal conjugate vaccine (PCV13).
42 Because of its thymus-independence, PPSV23 is associated with poor immunogenicity in
43 children under 2 years of age, and in immunocompromised patients. In addition, it does not
44 induce an anamnestic antibody response, and has been associated with decreased
45 responsiveness in case of multiple exposures. On the other hands, as a thymo-dependent
46 vaccine, PCV13 increases serotype-specific memory B-cell responses, and induces robust T-
47 cell-dependent memory responses (8).

48 Studies on the impact of anti-pneumococcal vaccination in patients with CKD,
49 including ESRD have demonstrated lower seroconversion rates, lower peak antibody titers, and
50 more rapid decline of immune correlates of protection as compared to other populations (13,14),
51 but they had limitations, including small sample size, retrospective design, or single-centre
52 design. Few studies assessed the impact of anti-pneumococcal vaccination on mortality and
53 morbidity in patients with ESRD, including patients on chronic dialysis (15)(16). To the best of
54 our knowledge, no study evaluated the clinical impact of various anti-pneumococcal vaccines

55 types, and schedules, in this population. The World Health Organization, doesn't recommend
56 anti-pneumococcal vaccination for healthy or immunocompromised adults in the absence of
57 robust evidence that it reduces morbidity and mortality in these populations, and because of the
58 herd effect of anti-pneumococcal vaccination in children (17). Contrarily to the 2022 advisory
59 committee on immunization practices (ACIP) guidelines (8), PPSV23 has long been
60 recommended in CKD patients, considered as 'immunocompetent patients with risk factors for
61 IPD'. French recommendations changed in 2017, when anti-pneumococcal vaccine schedules
62 were homogenized for all persons over 2 years with risk factor(s) for IPD: first, PCV13, then
63 PPSV23 two months later. Selection of those anti-pneumococcal vaccination schedules in USA
64 and in France were based on studies evaluating cost-effectiveness, quality-adjusted life years
65 gained, and averted IPD cases. No randomized controlled clinical trial documented the benefit
66 of anti-pneumococcal vaccines in patients with CKD or ESRD, or compared different
67 vaccination schedules in these populations.

68 Finally, current data suggest that anti-pneumococcal vaccination coverage is low in
69 patients with CKD and ESRD, in different countries (15,18,19). We aimed to determine anti-
70 pneumococcal vaccination coverage in patients who initiate chronic dialysis in France, the
71 current vaccination schedules, and their association with one-year mortality.

72

73 **2. Methods**

74 *2.1 Study design*

75 This study was performed in France, a country with health care system ensuring equal
76 access to primary care, free of charge, irrespective of social status and insurance coverage. We
77 cross-linked two prospective national databases: i) the renal epidemiology and information
78 network (REIN) registry, established in 2002, that covers all regions in the country since 2011,
79 and includes all patients on dialysis, either haemodialysis (HD), or peritoneal dialysis (PD), as
80 well as kidney transplant recipients (20); ii) the French national health insurance information
81 system (*système national d'information inter-régimes de l'assurance maladie*, SNIIRAM), a

82 claim database covering 97% of French inhabitants, which collects individual data on all health
83 expenditure reimbursements for people living in France. We enrolled all incident adult patients
84 (i.e., at least 18 year-old), who started dialysis therapy - HD or PD - in 2015 in France. We
85 extracted data from January 2013 to December 2016.

86 *2.2 Database linkage procedure*

87 In order to identify patients who received at least one anti-pneumococcal vaccine from
88 two years before, to one year after dialysis start, data from REIN registry were linked to data
89 from the SNIIRAM database. Because both databases contain anonymized patients
90 information, a deterministic linkage method has been developed, in order to merge information
91 from SNIIRAM to REIN, based on: sex, date of dialysis start (month and year), centre of first
92 dialysis, birth date (month and year), and city of residence. Thanks to this linkage procedure,
93 83% of REIN patients (n=8,294) have been identified in the SNIIRAM database (see flowchart,
94 Figure 1).

95 *2.3 Data collection*

96 From the REIN registry, we extracted socio-demographic data, primary kidney disease,
97 comorbidities, characteristics and context of dialysis start, and any medical event reported after
98 dialysis start. Primary outcome was all-cause mortality, mortality related to infection, and
99 mortality non-related to infection. Age was categorized in five groups (18-39, 40-59, 60-69, 70-
100 79, ≥ 80 years), serum albumin was categorized in two groups (<30 , ≥ 30 g/L), hemoglobin
101 level in three groups (<10 , 10-12, >12 g/dL); body mass index (BMI) in four groups (<18.5 ,
102 18.5-23, 23-25, ≥ 25 kg/m²), smoking status in two groups (never smoke, current/former
103 smoker), and context of dialysis start in two groups (emergency vs planned first dialysis). Data
104 related to anti-pneumococcal vaccination were extracted from the SNIIRAM database,
105 including type of vaccine (PPSV23 or PCV13, the two anti-pneumococcal vaccines available
106 during the study period), date of vaccination, and medical specialty of the prescribing

107 practitioner (general practitioner, nephrologist, others). Vaccinated patients were categorized in
108 three groups: PCV13 only, PPSV23 only, and PCV13 + PPSV23.

109

110 *2.4 Statistical analyses*

111 Patients baseline characteristics were expressed as frequencies and percentages for
112 categorical variables, and as mean (standard deviation) for continuous variables. Demographic
113 and clinical features were described by subgroups and compared using chi-square or exact
114 Fischer tests, according to anti-pneumococcal vaccine status: i) vaccinated vs non-vaccinated;
115 ii) non-vaccinated vs vaccinated with PPSV23 only vs vaccinated with PCV13 vs vaccinated
116 by PCV13 + PPSV23

117 Before the implementation of the survival models for each outcome, missing data were
118 handled by using multiple imputation by chained equations (MICE) with ten imputations and
119 five cycles. The association between patient-related data and one-year all-cause mortality was
120 assessed by using univariate and multivariate Cox proportional hazard models. Because few
121 patients died due to infectious causes, survival couldn't be studied specifically for this mortality
122 category. Time to outcome was measured from dialysis start to death, or the endpoint (at least
123 one year after dialysis start). Kaplan-Meier survival curves have been established and compared
124 using the log-rank test. Variables with a P -value <0.20 in univariable models were included in
125 the multivariable models. A P -value <0.05 was considered statistically significant. Results were
126 reported as hazard ratios (HR) with 95% confidence intervals (95% CI). All statistical analyses
127 were performed with the STATA 13.1 software.

128 *2.5 Ethics Statement*

129 This study was approved by the CERES (*Comité d'Expertise pour les Recherches, les*
130 *Études et les Évaluations dans le domaine de la Santé*) and the national committee for liberty
131 and data processing, the CNIL (*Commission Nationale de l'Informatique et des Libertés*).
132 Written informed consent was waived because patients enrolled in the REIN database were

133 3. Results

134 3.1 Patients characteristics

135 Of the 11,083 patients who started chronic dialysis in 2015 in France, 9,184 (82.9%)
136 could be linked in the two databases, and 8,294 (74.8% of total) were analysed (Figure 1). There
137 were 5,368 males (64.7%), and 2,926 females (35.3%), with a mean age of 68.5 ± 15.2 years
138 by the time dialysis was initiated (Table 1). Main primary causes of ESRD were hypertension
139 ($n=2242$, 27.0%), and diabetes ($n=1911$, 23.0%). Dialysis was started in emergency for 503
140 patients (27.2%), and could be planned for 1,346 (72.8%). Most patients started HD ($n=7578$,
141 91.4%), while only 716 (8.6%) started PD (Table 1).

142 3.2 Anti-pneumococcal vaccination

143 Overall, 1,849 patients (22.3%) received at least one anti-pneumococcal vaccine during
144 the 2 years before the dialysis initiation, and the year after. Compared with patients who
145 received no anti-pneumococcal vaccination, vaccinated patients were younger (mean, $66.5 \pm$
146 14.8 years vs. 69.0 ± 14.9 years, $P \leq 0.001$), more likely to be smoker or former smoker (41.4%
147 vs. 35.4%, $P \leq 0.001$), with chronic respiratory disease (19.8% vs. 15.1%, $P \leq 0.001$), to have
148 glomerulonephritis as primary cause of ESRD (17.0% vs. 11.0, $P \leq 0.001$), and less likely to
149 start dialysis in emergency (27.2% vs. 31.1%, $P=0.001$).

150 Regarding anti-pneumococcal vaccination schedules, patients who received PPSV23
151 alone were older, more likely to suffer from chronic respiratory disease, with cardiovascular
152 risk factors, malnutrition and diabetes, as compared to patients who received PCV13, alone or
153 in combination with PPSV23 (Table 2). Anti-pneumococcal vaccination has been mainly
154 prescribed by a general practitioner ($n=1161$, 62.8%), or by a nephrologist ($n=400$, 21.6%).
155 Nephrologists were more likely to prescribe PCV13, with or without PPSV23, while general
156 practitioners were more likely to prescribe PPSV23 alone.

157 Among vaccinated patients, 1,307 (70.7%) were vaccinated after dialysis start. Anti-
158 pneumococcal vaccination was more likely to be initiated after dialysis start in patients who
159 initiated dialysis in emergency (74%), and to include PCV13 with or without PPSV23

160 (respectively, 82.1% and 88.1%). Nephrologists represented only 5.9% of anti-pneumococcal
161 vaccine prescribers before dialysis start, but this proportion raised to 28.4% after dialysis start.

162 *3.3 Univariate and multivariate analysis of variables associated with mortality*

163 Of 8,294 patients analysed, 1,157 (13.9%) died. Causes of mortality in patients who
164 received the anti-pneumococcal vaccine, and those who did not, are reported in Table 3.
165 Unadjusted models showed that pneumococcal vaccination was associated with a decreased
166 hazard for death (HR 0.51, 95% CI 0.43-0.60, $P \leq 0.0001$, Figure 2). Association with survival
167 remained significant in subgroups of patients who received PCV13 + PPSV23 and PCV13
168 alone, but not in those who received PPSV23 alone. After adjustment for patient characteristics
169 and comorbidities, receipt of anti-pneumococcal vaccine was still associated with survival, with
170 a HR for death of 0.62 (95%CI, 0.52-0.73, $P \leq 0.0001$). Association with survival remained
171 independently significant in subgroups of patients who received PCV13 + PPSV23 (HR 0.37,
172 95%CI 0.28-0.51, $P \leq 0.0001$), and in those who received PCV13 alone (HR 0.35, 95%CI 0.19-
173 0.65, $P \leq 0.0001$), but not in those who received PPSV23 alone (HR 0.96, 95%CI 0.78-1.19,
174 $P=0.740$) (Table 4, Figure 3). Those results remained similar after adjustment on geographical
175 area, and inscription on transplantation list.

176

177 **3. Discussion**

178 The major findings of this nationwide prospective cohort study are the followings: i)
179 prescription of at least one anti-pneumococcal conjugate vaccine was independently associated
180 with survival in patients who started dialysis, after adjustment for major factors associated with
181 mortality; ii) anti-pneumococcal vaccine coverage was very low in France, in 2015, in this
182 population, estimated at 1,849/8,294 (22.3%), taking into account all anti-pneumococcal
183 vaccines received from two years prior, until one year after, dialysis start. Of note, prescription
184 of only PPSV23, in the absence of PCV13, was not associated with survival, in line with the

185 lower immunogenicity of polysaccharide vaccines in the absence of priming with conjugated
186 vaccine (21,22)(23)(24).

187 Infection is the second cause of death for patients with ESRD, especially in those who
188 require dialysis (1). Pneumococcal is among the most virulent, and the most common pathogens
189 reported in different case series. Hence, prevention of IPD is of paramount importance in
190 patients who start chronic dialysis. Our findings that anti-pneumococcal immunization that
191 includes conjugated anti-pneumococcal vaccine PCV13 is independently associated with
192 survival in this population strongly advocate for urgent actions to promote vaccine coverage in
193 countries where this is dramatically low, as in France. The rate of anti-pneumococcal vaccine
194 coverage in patients who started dialysis in France in 2015, although desperately low in this
195 study (i.e. less than one in four patients), is in line with estimates in other groups with official
196 recommendations for anti-pneumococcal vaccination in France (25)(26). Previous studies on
197 anti-pneumococcal vaccine coverage in patients who start dialysis have documented broad
198 heterogeneity from one country to another: estimated at 45.5% in the United States (15), but
199 similar to our findings in England, at 22% (19). This heterogeneity probably reflects a broad
200 area of parameters, including vaccine hesitancy, robustness of immunization programme in the
201 general population and in at-risk categories, as well as health care systems. In line with previous
202 studies on the same population in other countries (15,25,26), patients who combine different
203 indications for anti-pneumococcal vaccination, including smokers, patients with chronic
204 respiratory diseases and elderly patients, had better vaccine coverages in our study, although
205 the rates remain well below the objectives.

206 Previous studies have found an association between anti-pneumococcal vaccine coverage
207 in patients on chronic dialysis, and survival, with adjusted HR from 0.76 to 0.89 (15), but the
208 impact of pneumococcal vaccine type (i.e. polysaccharide vs conjugated, or a combination of
209 both), could not be ascertained. The prevention of IPD by PPSV23 has been documented in
210 different populations (21,23,24). PPSV23 immunogenicity is impaired in immunocompromised
211 patients, and its clinical effectiveness remains uncertain in many settings. A landmark hospital-

212 based case-control study from 1984 to 1990 estimated the protection afforded by PPSV23 in
213 adults at 56% overall: 61% in immunocompetent and 21% in immunocompromised (24).
214 Among patients with CKD, PPSV23 protection against IPD was estimated at 27%, with a broad
215 95%CI (-52% to 78%), and no or limited impact on survival (16,22,27,28). Andrews et al.
216 estimated PPSV23 protective effect against IPD at 60-65% among elderly patients between the
217 ages of 65 and 84 years, with no significant protection, in the absence of conjugated vaccines
218 in patients older than 85 years and in immunocompromised patients. In addition, protection was
219 estimated to be lost in medium- and high-risk patients 5 years after PPSV23 vaccination (29).

220 To the best of our knowledge, our study is the first clinical study to compare different anti-
221 pneumococcal vaccine schedules in patients with ESRD. We found that schedules including
222 one conjugate vaccine (i.e. PCV13, the only conjugated anti-pneumococcal vaccine available
223 in France during the study period and up to 2023), were independently associated with one year-
224 survival after adjustment on major cofactors, while PPSV23 was not. Although primarily
225 developed for infants and toddlers, the immunogenicity of PCV13 has been well documented
226 in adults (30): In two randomized controlled trials (30,31), serotype-specific opsono-phagocytic
227 activity responses were more robust after PCV13 than after PPSV23 for 8 of the 12 serotypes
228 targeted by both vaccines, among non-immunocompromised adults with chronic diseases at risk
229 of IPD. PCV13 efficacy has also been documented in people living with HIV (32), and in
230 healthy patients >65 year-old (33). Although not supported by any randomized clinical trial, the
231 theoretical advantages of anti-pneumococcal conjugated vaccines include more robust initial
232 immune response, especially in patients with impaired immunity related to age, or any other
233 conditions, longer persistence of protection, and limited or no loss of efficacy with repeated
234 administration over time. In addition, the nature of the first anti-pneumococcal vaccine may be
235 particularly important, due to the priming effect: vaccine schedules initiated by PPSV23 would
236 elicit sub-optimal immune responses, as compared to vaccine schedules using conjugated
237 vaccines as the primer anti-pneumococcal vaccine. For all these reasons, French guidelines
238 recommend one dose of PCV13 followed by one dose of PPSV23 at least 8 weeks later, then

239 another dose of PPSV23 at least 5 years after previous PPSV23, in patients with CKD not
240 previously vaccinated (34). Our findings are in line with these recommendations, although we
241 were not adequately powered to estimate i) the consequences of using PPSV23 as the first anti-
242 pneumococcal vaccine; ii) the impact of time elapsed between PCV13, and PPSV23
243 administration.

244 Our study has limitations: Firstly, due to its observational design, potential biases may be
245 involved, and no causal link can be inferred from the association between anti-pneumococcal
246 vaccine, and survival, although it remained significant on multivariate analysis after
247 adjustment. For example, patients who were vaccinated may have been followed by doctors
248 more aware of guidelines, which may also imply better management of other comorbidities
249 (hypertension, diabetes, etc.). We could not control these potential biases. Secondly, our
250 findings apply to the situation in France, during years 2013-2016, but it may not be
251 generalizable, as differences in population of patients who initiate dialysis, in practices, and in
252 health care systems, may modify the association between anti-pneumococcal vaccination, and
253 survival. In particular, due to the herd effect, the impact of anti-pneumococcal vaccine in
254 patients who start dialysis may be more limited in countries with higher anti-pneumococcal
255 vaccine coverage overall. Thirdly, we had no information about pneumococcal vaccine outside
256 of the study period (i.e. 2013-2016). Hence patients who were vaccinated before 2013 have
257 been misclassified as unvaccinated, although they may have been at least partly protected. In
258 addition, our follow-up was limited at one year after dialysis start, so that we could not estimate
259 association with long-term outcome. Finally, our study was performed before the advent of the
260 20-valent pneumococcal conjugated vaccine (PCV20), which may change the impact of anti-
261 pneumococcal vaccine, as well as recommended schedules, as the benefit of secondary PPSV23
262 vaccine will necessarily be reduced in terms of expanded serotypes coverage. Indeed, PCV20
263 provides additional protection against serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F as
264 compared to PCV13. The proportion of strains responsible for IPD in 2021 in France included
265 in conjugated vaccines was 23.6% for PCV13, 27.4% for PCV15, and 56.9% for PCV20 (35).

266 PPSV23 would only marginally expand this coverage. Our study also has strengths, including
267 large sample size, prospective and standardized collection of data, and fair representability, as
268 75% of all patients who initiated dialysis in France in 2015 were enrolled.

269 In conclusion, we found that prescription of at least one anti-pneumococcal conjugate
270 vaccine was independently associated with one-year survival in patients who start dialysis.
271 Given the low anti-pneumococcal vaccine coverage in many countries, these findings advocate
272 for actions to promote anti-pneumococcal vaccine in patients with ESRD, ideally before
273 dialysis start, with conjugated anti-pneumococcal vaccine followed by PPSV23 at least 8 weeks
274 later, pending the advent of PCV20.

275

276

277 **Funding**

278 This research did not receive any specific grant from funding agencies in the public,
279 commercial, or not-for-profit sectors.

280

281 **Declaration of Competing Interest**

282 The authors declare that they have no known competing financial interests or personal
283 relationships that could have influenced the work reported in this paper

284

285 **References**

- 286 1. Wen CP, Cheng TYD, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause
287 mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293
288 adults in Taiwan. *The Lancet*. juin 2008;371(9631):2173-82.
- 289 2. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal
290 disease compared with the general population. *Kidney Int*. oct 2000;58(4):1758-64.
- 291 3. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage
292 renal disease. *Chest*. déc 2001;120(6):1883-7.
- 293 4. Vandecasteele SJ, Ombelet S, Blumental S, Peetermans WE. The ABC of
294 pneumococcal infections and vaccination in patients with chronic kidney disease. *Clin Kidney*
295 *J*. juin 2015;8(3):318-24.
- 296 5. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A
297 prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J*
298 *Med*. 23 janv 1997;336(4):243-50.
- 299 6. James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, et al. CKD and risk
300 of hospitalization and death with pneumonia. *Am J Kidney Dis Off J Natl Kidney Found*. juill
301 2009;54(1):24-32.
- 302 7. Backhaus E, Berg S, Andersson R, Ockborn G, Malmström P, Dahl M, et al.
303 Epidemiology of invasive pneumococcal infections: manifestations, incidence and case
304 fatality rate correlated to age, gender and risk factors. *BMC Infect Dis*. 3 août 2016;16:367.
- 305 8. Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-
306 Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine
307 Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization
308 Practices - United States, 2022. *MMWR Morb Mortal Wkly Rep*. 28 janv 2022;71(4):109-17.
- 309 9. Ma BM, Yap DYH, Yip TPS, Hung IFN, Tang SCW, Chan TM. Vaccination in patients
310 with chronic kidney disease-Review of current recommendations and recent advances.
311 *Nephrol Carlton Vic*. janv 2021;26(1):5-11.
- 312 10. Krueger KM, Ison MG, Ghossein C. Practical Guide to Vaccination in All Stages of
313 CKD, Including Patients Treated by Dialysis or Kidney Transplantation. *Am J Kidney Dis Off*
314 *J Natl Kidney Found*. mars 2020;75(3):417-25.
- 315 11. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients
316 with renal disease. *Am J Kidney Dis Off J Natl Kidney Found*. déc 2005;46(6):997-1011.
- 317 12. Robinson J. Efficacy of pneumococcal immunization in patients with renal disease--
318 what is the data? *Am J Nephrol*. août 2004;24(4):402-9.
- 319 13. Cosio FG, Giebink GS, Le CT, Schiffman G. Pneumococcal vaccination in patients

- 320 with chronic renal disease and renal allograft recipients. *Kidney Int.* août 1981;20(2):254-8.
- 321 14. Kausz A, Pahari D. The value of vaccination in chronic kidney disease. *Semin Dial.*
- 322 févr 2004;17(1):9-11.
- 323 15. Gilbertson DT, Guo H, Arneson TJ, Collins AJ. The association of pneumococcal
- 324 vaccination with hospitalization and mortality in hemodialysis patients. *Nephrol Dial*
- 325 *Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* sept 2011;26(9):2934-9.
- 326 16. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al. Efficacy of
- 327 pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. *Arch*
- 328 *Intern Med.* 12 déc 1994;154(23):2666-77.
- 329 17. Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal
- 330 vaccination: an ongoing challenge. *Pneumonia.* 25 sept 2022;14(1):5.
- 331 18. Kopp A, Mangin O, Gantzer L, Lekens B, Simoneau G, Ravelomanantsoa M, et al.
- 332 Pneumococcal vaccination coverage in France by general practitioners in adults with a high
- 333 risk of pneumococcal disease. *Hum Vaccines Immunother.* 2 janv 2021;17(1):162-9.
- 334 19. Wilmore SMS, Philip KE, Cambiano V, Bretherton CP, Harborne JE, Sharma A, et al.
- 335 Influenza and pneumococcal vaccinations in dialysis patients in a London district general
- 336 hospital. *Clin Kidney J.* févr 2014;7(1):27-32.
- 337 20. Couchoud C, Stengel B, Landais P, Aldigier JC, de Cornelissen F, Dabot C, et al. The
- 338 renal epidemiology and information network (REIN): a new registry for end-stage renal
- 339 disease in France. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.*
- 340 févr 2006;21(2):411-8.
- 341 21. Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal Vaccination
- 342 Strategies. An Update and Perspective. *Ann Am Thorac Soc.* juin 2016;13(6):933-44.
- 343 22. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing
- 344 pneumococcal infection in adults. *Cochrane Acute Respiratory Infections Group*, éditeur.
- 345 *Cochrane Database Syst Rev* [Internet]. 31 janv 2013 [cité 12 févr 2023]; Disponible sur:
- 346 <https://doi.wiley.com/10.1002/14651858.CD000422.pub3>
- 347 23. Falkenhorst G, Renschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan
- 348 C. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against
- 349 Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. *PloS One.*
- 350 2017;12(1):e0169368.
- 351 24. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The
- 352 protective efficacy of polyvalent pneumococcal polysaccharide vaccine. *N Engl J Med.* 21
- 353 nov 1991;325(21):1453-60.
- 354 25. Brocq O, Acquacalda E, Berthier F, Albert C, Bolla G, Millasseau E, et al. Influenza
- 355 and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic

356 inflammatory joint: A retrospective study. *Joint Bone Spine*. mars 2016;83(2):155-9.

357 26. Wyplosz B, Fernandes J, Sultan A, Roche N, Roubille F, Loubet P, et al.

358 Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French

359 national observational study. *Vaccine*. août 2022;40(33):4911-21.

360 27. Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the

361 pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for

362 pneumonia. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 1 juill 2010;51(1):15-22.

363 28. Ortvist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, et al. Randomised

364 trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia

365 in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. *Lancet*

366 *Lond Engl*. 7 févr 1998;351(9100):399-403.

367 29. Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness

368 of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in

369 the elderly in England and Wales. *Vaccine*. 6 nov 2012;30(48):6802-8.

370 30. Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al.

371 Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years

372 of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

373 *Vaccine*. 2 août 2013;31(35):3585-93.

374 31. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, et al.

375 Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-

376 valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. *Vaccine*.

377 2 août 2013;31(35):3577-84.

378 32. Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, et al.

379 Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected

380 individuals naïve to pneumococcal vaccination. *AIDS Lond Engl*. 17 juill

381 2015;29(11):1345-54.

382 33. Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al.

383 Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med*.

384 19 mars 2015;372(12):1114-25.

385 34. Kim DK, Hunter P. Advisory Committee on Immunization Practices Recommended

386 Immunization Schedule for Adults Aged 19 Years or Older — United States, 2019.


387 2019;68(5).

388 35. Plainvert C, Varon E, Viriot D, Kempf M, Plainvert C, Alauzet C, et al. Invasive


389 pneumococcal infections in France: Changes from 2009 to 2021 in antibiotic resistance and

390 serotype distribution of *Streptococcus pneumoniae* based on data from the French Regional


391 Pneumococcal Observatories network. *Infect Dis Now*. 2023;53(1):104632.



393 **Figure 2.** Kaplan-Meier survival curve one year after dialysis start according to anti-



394 **Figure 3.** Kaplan-Meier survival curve one year after dialysis start according to anti-
395 pneumococcal vaccination schedule (upper lines: patients who received the 13-valent
396 conjugated vaccine, with or without 23-valent polysaccharide vaccine; lower lines, patients not-
397 vaccinated, or who received only the 23-valent polysaccharide vaccine)
398



Characteristics	Pneumococcal vaccination			P-value
	All, <i>n</i> (%)	Vaccinated, <i>n</i> (%)	Not vaccinated, <i>n</i> (%)	
All	8,294 (100)	1,849 (100)	6,645 (100)	
Age, years	68.5 (15.2)	66.5 (14.8)	69.0 (14.9)	≤0.001
Sex				
• Men	5368 (64.7)	1244 (67.28)	4124 (63.99)	0.009
• Women	2926 (35.3)	605 (32.72)	2321 (36.01)	
Dialysis characteristics				
- Primary cause of ESRD				
• Hypertension	2242 (27.0)	461 (24.93)	1781 (27.63)	≤0.001
• Diabetes	1911 (23.0)	338 (18.28)	1573 (24.41)	
• Glomerulonephritis	1024 (12.4)	314 (16.98)	710 (11.02)	
• Other	1887 (22.8)	451 (24.39)	1436 (22.28)	
• Unknown	1230 (14.8)	285 (15.41)	945 (14.66)	
- Context of dialysis start				
• planned	5787 (69.8)	1346 (72.8)	4441 (68.9)	0.001
• emergency	2507 (30.2)	503 (27.2)	2004 (31.1)	
- Dialysis modality				
• Hemodialysis	7578 (91.4)	1684 (91.1)	5894 (91.4)	0.613
• Peritoneal dialysis	716 (8.6)	165 (8.9)	551 (8.6)	
Comorbid conditions				
- BMI, kg/m ²	26.75	26.86	26.71	0.399
- Tobacco				
• Non-smoker	3895 (47.0)	773 (41.8)	3122 (48.4)	≤0.001
• Active/former	3047 (36.7)	765 (41.4)	2282 (35.4)	
• Unknown	1352 (16.3)	311 (16.8)	1041(16.2)	
- Chronic respiratory disease	1342 (16.2)	366 (19.8)	976 (15.1)	≤0.001
- Cardiovascular risk factors				
• 1	2028 (24.5)	463 (25.0)	1565 (24.3)	≤0.001
• ≥ 2	2572 (31.0)	479 (25.9)	2093 (32.5)	
- Diabetes	3701 (44.6)	734 (39.7)	2967 (46.0)	≤0.001
- Cancer	854 (10.3)	161 (8.7)	693 (10.8)	0.038
- Immunosuppression				
• HIV	61 (0.7)	26 (1.4)	35 (0.5)	0.001
- Serum albumin, g/L	34.3 (6.1)	34.8 (6.1)	34.3 (6.1)	0.09
- Hemoglobin, g/dL	10.1 (1.6)	10.3 (1.6)	10.1 (1.6)	0.004

400 * BMI, body mass index; HIV, human immunodeficiency virus

401 Quantitative data are presented as mean (standard deviation), qualitative data as numbers (%)

402 **Table 2.** Patients characteristics according to pneumococcal vaccination schedules

Characteristics	Pneumococcal Vaccination Schedules			P-value
	PPSV23, <i>n</i> (%)	PCV13 + PPSV23, <i>n</i> (%)	PCV13, <i>n</i> (%)	
All	650	938	261	
Age, years	73.4 (11.25)	62.7 (13.4)	62.1 (15.5)	0.0001
Sex				0.135
• Men	421 (64.8)	651 (69.4)	172 (65.9)	
• Women	229 (35.2)	287 (30.6)	89 (34.1)	
Dialysis characteristics				
Primary cause of ESRD				≤ 0.001
• Hypertension	206 (31.7)	194 (20.7)	61 (23.4)	
• Diabetes	127 (19.5)	169 (18.0)	42 (16.1)	
• Glomerulonephritis	87 (13.4)	185 (19.7)	42 (16.7)	
• Other	130 (20.0)	245 (26.1)	76 (29.1)	
• Unknown	100 (15.4)	145 (15.5)	40 (15.3)	
Context of dialysis start				0,395
• planned	471 (72.5)	676 (72.1)	199 (76.2)	
• emergency	179 (27.5)	262 (27.9)	62 (23.8)	
Dialysis modality				0.497
• Hemodialysis	598 (92.0)	852 (90.8)	234 (89.7)	
• Peritoneal dialysis	52 (8.0)	86 (9.2)	27 (10.3)	
Comorbid conditions				
- BMI, kg/m ²	27.6 (6.2)	26.4 (5.7)	26.6 (7.1)	0.183
- Tobacco				0.045
• Non-smoker	282 (43.4)	381 (40.6)	110 (42.2)	
• Active / Former	252 (38.8)	412 (43.9)	101 (38.7)	
• Unknown	116 (17.9)	145 (15.5)	50 (19.2)	
- Chronic respiratory failure	183 (28.2)	154 (16.4)	29 (11.1)	≤ 0.001
- Vascular risk factors				≤ 0.001
• 1	187 (28.8)	214 (22.8)	62 (23.8)	
• ≥ 2	218 (33.5)	203 (21.6)	58 (22.2)	
- Diabetes	295 (45.4)	351 (37.4)	88 (33.7)	≤ 0.001
- Cancer	66 (10.2)	74 (7.9)	21 (8.1)	0.479
- HIV	2 (0.3)	18 (1.9)	6 (2.3)	0.010
Vaccine prescriber				≤ 0.001
- General practitioner	487 (74.9)	541 (57.7)	133 (51.0)	
- Nephrologist	87 (13.4)	229 (24.4)	84 (32.2)	
- Others / unknown	76 (11.7)	168 (17.9)	44 (16.9)	
Vaccination Time				≤ 0.001
• Before dialysis	343 (52.8)	168 (17.9)	31 (11.9)	
• After dialysis start	307 (47.2)	770 (82.1)	230 (88.1)	

403 * BMI, Body Mass Index; HIV, Human Immunodeficiency Virus; PPSV23, 23-valent pneumococcal
 404 polysaccharide vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; ESRD, end-stage renal
 405 disease. Quantitative data are presented as mean (standard deviation), qualitative data as numbers (%)

406 **Table 3.** Causes of mortality according to pneumococcal vaccination status

Causes of mortality	Deaths among vaccinated patients, <i>n</i> (%)	Deaths among non-vaccinated patients, <i>n</i> (%)	<i>P</i> -value
All	153	1004	0.292
- Infections	20 (13.1)	166 (16.5)	0.364
- Cardiovascular diseases	49 (32.0)	258 (25.7)	--
- Kidney diseases	2 (1.3)	9 (0.9)	--
- Respiratory diseases	7 (4.6)	30 (3.0)	--
- Liver diseases	0	8 (0.8)	--
- Cancer	22 (14.4)	114 (11.4)	--
- Diabetes	0	1 (0.1)	--
- Others	27 (17.7)	218 (21.7)	--
- Unknown	26 (17.0)	200 (19.9)	--

407

408

409

410

411 **Table 4.** Univariate and multivariate analysis of risk factors for death

Variables	Univariate Cox model		Multivariate Cox model	
	Hazard Ratio (95%CI)	<i>P</i> -value	Hazard Ratio (95%CI)	<i>P</i> -value
- Age >65 years	3.44 (2.91 – 4.06)	≤ 0.0001	2.28 (1.91 – 2.71)	≤ 0.0001
- Female	1.03 (0.92 – 1.17)	0.543	1.06 (0.94 – 1.21)	0.343
- Cause of ESRD				
• Hypertension	2.14 (1.68 – 2.71)	≤0.0001	1.25 (0.98 – 1.60)	0.076
• Diabetes	1.58 (1.23 – 2.03)	≤0.0001	1.07 (0.83 – 1.39)	0.595
• Other	1.78 (1.39 – 2.27)	≤0.0001	1.39 (1.08 – 1.79)	0.011
• Unknown	2.10 (1.63 – 2.72)	≤0.0001	1.34 (1.03 – 1.74)	0.028
- Dialysis start in emergency	1.66 (1.47 – 1.86)	≤0.0001	1.19 (1.06 – 1.35)	0.005
- Peritoneal dialysis	1.01 (0.82 – 1.23)	0.950	--	--
- Initial catheter in hemodialysis	2.20 (1.94 – 2.49)	≤0.0001	--	--
- BMI <18.5 kg/m ²	1.57 (1.18 – 2.09)	0.002	1.52 (1.12 – 2.06)	0.008
- Smoker	1.00 (0.86 – 1.17)	0.953	--	--
- Chronic respiratory failure	1.81 (1.57 – 2.09)	≤0.0001	1.26 (1.07 – 1.47)	0.004
- Vascular risk factors				
• 1	1.93 (1.64 – 2.27)	≤0.0001	1.42 (1.21 – 1.68)	≤ 0.0001
• ≥2	2.99 (2.59 – 3.45)	≤0.0001	1.89 (1.61 – 2.21)	≤ 0.0001
- Diabetes	1.12 (1.00 – 1.26)	0.047	--	--
- Liver disease	2.48 (1.92 – 3.20)	≤0.0001	2.71 (2.06 – 3.56)	≤ 0.0001
- Cancer	2.73 (2.37 – 3.14)	≤0.0001	2.20 (1.91 – 2.54)	≤ 0.0001
- Serum albumin <30 g/L	2.26 (1.99 – 2.56)	≤0.0001	1.69 (1.48 – 1.93)	≤ 0.0001
- Hemoglobin <10 g/dL	1.35 (1.18 – 1.54)	≤0.0001	--	--
Anti-pneumococcal vaccine	0.51 (0.43– 0.60)	≤0.0001	0.62 (0.52 – 0.73)	≤ 0.0001
Vaccination schedules				
- PPSV23 alone	0.97 (0.79 – 1.20)	0.799	0.96 (0.78 – 1.19)	0.740
- PCV13 + PPSV23	0.28 (0.21 – 0.38)	≤0.0001	0.37 (0.28 – 0.51)	≤ 0.0001
- PCV 13 alone	0.23 (0.12 – 0.43)	≤0.0001	0.35 (0.19 – 0.65)	≤ 0.0001

412 *CI: Confidence Interval; ESRD, End-Stage Renal Disease; BMI, Body Mass Index; PPSV23, 23-valent

413 Pneumococcal PolySaccharide Vaccine; PCV13, 13-valent Pneumococcal Conjugate Vaccine.